Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease

American Journal of Cardiology

Volumn 88, Issue 3, 2001, Pages 236-242

  Catella Lawson, Francesca ^a   Kapoor, Shiv ^b   Moretti, Deborah ^a   De Marco, Susan ^a   Vigilante, Gary J ^c   Cucchiara, Andrew J ^b   Ramsey, Karen E ^d   Combe, Sophie ^d   Rocca, Bianca ^a   Theroux, Pierre ^e   FitzGerald, Garret A ^a,c  

^a Center for Experimental Therapeutics   (United States)

^b General Clinical Research Center   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d SANOFI   (France)

^e MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; ASPIRIN; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA; THROMBOXANE B2;

EID: 0035421784     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01632-0     Document Type: Article

References (29)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Effect of the platelet glycoprotein II/IIIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization
3. Randomized placebo-controlled trial of abciximab before and during intervention in refractory unstable angina: The CAPTURE study
4. Randomized controlled trial to assess safety of coronary stenting with use of abciximab
5. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
6. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
7. Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation
8. Effects of competitive platelet glycoprotein IIb/IIIa inhibition with integrelin in reducing complications of percutaneous coronary intervention
9. Effects of platelet glycoprotein IIb IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina
10. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
11. Long-term treatment with a platelet glycoprotein receptor antagonist after percutaneous coronary revascularization
12. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16 trial)
13. 2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty
14. 3) inhibitors
15. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of the TIMI 15A and 15B trials
16. 2 production in healthy subjects
17. 2. An index of thromboxane formation in the human circulation
18. 2 metabolites in humans
19. 2 in the human circulation
20. Measurement of thromboxane metabolites by gas chromatography-mass spectrometry
21. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion
22. Thrombin-receptor agonist peptides, in contrast to thrombin itself, are not full agonists for activation and signal transduction in human platelets in the absence of platelet-derived secondary mediators
23. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men
24. Glycoprotein IIb/IIIa antagonists. Potential induction and detection of drug-dependent antiplatelet antibodies
25. Understanding thrombocytopenia and antigenicity with glycoprotein IIb/IIIa inhibitors
26. 3 in resting and activated human platelets determined by expression of a novel class of ligand-induced binding sites (LIBS) recognized by monoclonal antibody AP-6
27. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa
28. Assays for heparin-induced thrombocytopenia
29. Comaparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strenght induced by tissue factor with use of thromboelastography: Differentiation among glycoprotein IIb/IIIa antagonists